SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Skip Navigation Links
Home
»
The Company
»
Scientific Publications
Scientific Publications
Scientific publications related to Diamyd Medicals research and development.
A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes
Diabetes Obes Metab. 2023 Aug 14; 25(11):3400-3409
Phase III, randomised, double-blind, placebo-controlled, multicentre trial to evaluate the efficacy and safety of rhGAD65 to preserve endogenous beta cell function in adolescents and adults with recently diagnosed type 1 diabetes, carrying the genetic HLA DR3-DQ2 haplotype: the DIAGNODE-3 study protocol
BMJ Open. 2022 Oct 31;12(10):e061776
Intralymphatic GAD-Alum (Diamyd
®
) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
J Clin Endocrinol Metab. 2022 Aug 18;107(9):2644-2651
Association between treatment effect on C-peptide preservation and HbA1c in meta-analysis of glutamic acid decarboxylase (GAD)-alum immunotherapy in recent-onset type 1 diabetes
Diabetes Obes Metab. 2022 April 17;24(8):1647-1655.
Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
Acta Diabetol. 2022 Jan 31; 59(5): 687–696
Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial
Diabetes Care. 2021 Jul;44(7):1604-1612.
More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes
N Engl J Med. 2017 Jul 27;377(4):403
Intralymphatic Injection of Autoantigen in Type 1 Diabetes
N Engl J Med. 2017 Feb 16;376(7):697-699
GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis
Diabetologia. 2017 Jan;60(1):43-49
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research